Chester County News and Community Website
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) released its third-quarter financial results for 2024, reporting key advancements in its clinical-stage therapeutic candidates. The company is making significant strides in …
Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) recently showcased preliminary safety results for its WEE1 inhibitor, APR-1051, at the EORTC-NCI-AACR Symposium in Barcelona. This data comes from ACESOT-1051, a Phase …
Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a prominent player in the biotechnology sector, is set to take part in the Maxim Healthcare Virtual Summit this week. The company’s President …
Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) is set to present four significant abstracts at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, scheduled for October 23-25, 2024, in …
Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced the appointment of Dr. Philippe Pultar as its senior medical advisor to bolster the development of APR-1051, a promising WEE1 inhibitor. …
Aprea Therapeutics Welcomes Dr. Philippe Pultar as Senior Medical Advisor Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that its President and CEO, Dr. Oren Gilad, will present at the Lytham Partners Fall 2024 Investor Conference on October 1.
Aprea Therapeutics to Present at Lytham Partners Fall Investor Conference Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) will deliver a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9 to 11, …
Aprea Therapeutics to Present at H.C. Wainwright Investment Conference Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has released its financial results for the second quarter ending June 30, 2024, alongside significant business updates that highlight the company’s strategic …
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Progress in Clinical Trials Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) will host a virtual Key Opinion Leader (KOL) event on June 24, 2024, at 9:00 AM ET to discuss APR-1051, their highly …
Aprea Therapeutics Hosts Virtual Event on Promising Cancer Therapy Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that the first patient has been dosed in its Phase 1 ACESOT-1051 study. The trial is evaluating APR-1051, a daily oral …
Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug Read More